PDF(Pubmed)
Abstract：
Neurological disorders, ranging from acute forms such as stroke and traumatic brain injury to neurodegenerative diseases like dementia, are the leading cause of disability-adjusted life years (DALYs) worldwide. A promising approach to address these conditions and promote nervous system regeneration is the use of the neuropeptide preparation Cerebrolysin, which has been shown to be effective in both clinical and preclinical studies. Despite claims of similar clinical efficacy and safety by several peptide preparations, concerns regarding their generic composition and efficacy have been previously raised. Based on these reports, we analyzed the peptide composition and neurotrophic activity of several peptide preparations allegedly similar to Cerebrolysin and approved in some countries for treating neurological diseases. Our results demonstrate that these preparations lack relevant biological activity and that the peptide composition is significantly different from Cerebrolysin. peptide.
摘要：
神经系统疾病,从中风和创伤性脑损伤等急性形式到痴呆等神经退行性疾病，是全球残疾调整寿命年(DALYs)的主要原因。解决这些情况和促进神经系统再生的有希望的方法是使用神经肽制剂脑活素，已在临床和临床前研究中被证明是有效的。尽管几种肽制剂声称具有相似的临床疗效和安全性，之前已经提出了对其通用成分和功效的担忧。根据这些报告,我们分析了几种据称类似于脑活素的肽制剂的肽组成和神经营养活性，并在一些国家批准用于治疗神经系统疾病。我们的结果表明，这些制剂缺乏相关的生物活性，并且肽组成与脑活素明显不同。肽。
